Cancers 2011, 3(1), 241-251; doi:10.3390/cancers3010241
Review

Targeting Apoptosis Signaling in Pancreatic Cancer

Simone Fuldaemail
Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Komturstr. 3a, 60528 Frankfurt, Germany
Received: 24 November 2010; in revised form: 5 January 2011 / Accepted: 6 January 2011 / Published: 11 January 2011
PDF Full-text Download PDF Full-Text [218 KB, uploaded 11 January 2011 12:19 CET]
Abstract: The ability to escape apoptosis or programmed cell death is a hallmark of human cancers, for example pancreatic cancer. This can promote tumorigenesis, since too little cell death by apoptosis disturbs tissue homeostasis. Additionally, defective apoptosis signaling is the underlying cause of failure to respond to current treatment approaches, since therapy-mediated antitumor activity requires the intactness of apoptosis signaling pathways in cancer cells. Thus, the elucidation of defects in the regulation of apoptosis in pancreatic carcinoma can result in the identification of novel targets for therapeutic interference and for exploitation for cancer drug discovery.
Keywords: apoptosis; pancreatic cancer; TRAIL; IAPs; mitochondria

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Fulda, S. Targeting Apoptosis Signaling in Pancreatic Cancer. Cancers 2011, 3, 241-251.

AMA Style

Fulda S. Targeting Apoptosis Signaling in Pancreatic Cancer. Cancers. 2011; 3(1):241-251.

Chicago/Turabian Style

Fulda, Simone. 2011. "Targeting Apoptosis Signaling in Pancreatic Cancer." Cancers 3, no. 1: 241-251.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert